This study is for adults with chronic heart failure (HF) who have
a reduced left ventricular ejection fraction (LVEF) of less than 40%. People can
join the study if they have been diagnosed with chronic HF at least 3 months
before the study. The purpose of this study is to find out whether a medicine
called vicadrostat, in combination with another medicine called empagliflozin,
helps people with chronic heart failure.